Antibodies

24 October 2023

Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023

24 October 2023

Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2

24 October 2023

Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2

24 October 2023

Bicara Therapeutics Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023

24 October 2023

ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

24 October 2023

ImmuneOncia Announces Phase 1 Results of CD47 Antibody at ESMO 2023

24 October 2023

ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

24 October 2023

Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial

24 October 2023

Salubris Biotherapeutics Presents Positive Initial Data from Phase 1b/2 Clinical Trial of JK08 at the European Society for Medical Oncology Annual Congress 2023

24 October 2023

OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody

24 October 2023

EpCAM, a broadly expressed, validated cancer target rescued by novel antibody technologies

23 October 2023

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

23 October 2023

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

23 October 2023

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer

23 October 2023

Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial

23 October 2023

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

23 October 2023

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

23 October 2023

ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

23 October 2023

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

22 October 2023

GSK enters exclusive license agreement with Hansoh for HS-20089

22 October 2023

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

22 October 2023

New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60 Percent Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive Non-Small Cel

22 October 2023

IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone

22 October 2023

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

22 October 2023

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

22 October 2023

Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer

22 October 2023

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

22 October 2023

Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

20 October 2023

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

20 October 2023

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

B7-H4 Targeted Antibody Therapy Pipeline Review

Aflibercept (Eylea) Biosimilars Pipeline Review

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Adalimumab (Humira) Biosimilars Pipeline Review